ZP3022
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research[1].
Product Specifications
CAS Number
1345835-12-2
UNSPSC
12352209
Target
GCGR
Type
Peptides
Related Pathways
GPCR/G Protein
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/zp3022.html
Purity
98.00
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NCCOCCOCC(N[C@@H](CC1=CC=C(C=C1)O)C(NCC(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC4=CC=CC=C4)C(N)=O)=O)=O)=O)=O)=O)=O)COCCOCCNC([C@H](CC(N)=O)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC5=CNC6=CC=CC=C56)NC([C@H](CCC(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC7=CC=CC=C7)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](CCSC)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC8=CC=CC=C8)NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(O)=O)NC(CNC([C@H](CC9=CNC=N9)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Molecular Formula
C199H294N48O61S
Molecular Weight
4366.81
References & Citations
[1]Dalbøge LS, et al. The novel GLP-1-gastrin dual agonist ZP3022 improves glucose homeostasis and increases β-cell mass without affecting islet number in db/db mice. J Pharmacol Exp Ther. 2014;350 (2) :353-360.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
